NAGE
Niagen Bioscience Inc
1W: -0.7%
1M: -11.6%
3M: -32.6%
YTD: -27.7%
1Y: -40.5%
3Y: +189.7%
5Y: -60.8%
$4.52
-0.02 (-0.44%)
After Hours: $4.46 (-0.06, -1.33%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$3.0M
Congress—
ETF Holdings—
Key Statistics
Market Cap$362.0M
52W Range4.39-14.69
Volume656,784
Avg Volume1,226,027
Beta2.23
Dividend—
Analyst Ratings
Company Info
CEORobert N. Fried
Employees104
SectorHealthcare
IndustryBiotechnology
IPO Date2015-06-24
Websiteniagenbioscience.com
10900 Wilshire Blvd, Suite 600
Los Angeles, CA 90024
US
Los Angeles, CA 90024
US
310 388 6706
About Niagen Bioscience Inc
Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.
Latest News
Niagen Bioscience increases share repurchase program to $20M
Why Veeva Systems Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
Niagen Bioscience Rallies 18% After Hours: Here's Why
U.S. expands Latin America drug fight with joint operation in Ecuador
Niagen Bioscience targets 10–15% revenue growth for 2026 while expanding injectable product line
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Lopez Carlos Luis | A-Award | 41,420 | $4.94 | 2026-02-19 |
| Pamir Ozan | A-Award | 62,131 | $4.94 | 2026-02-19 |
| Fried Robert N | A-Award | 503,937 | $4.94 | 2026-02-19 |
| Pamir Ozan | P-Purchase | 4,465 | $6.81 | 2025-11-14 |
| Pamir Ozan | P-Purchase | 2,220 | $6.85 | 2025-11-14 |